Full Press Release Details
Fennec Announces Proposed Public Offering
Research Triangle Park, N.C., April
29, 2020 - Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development
of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity from cisplatin
in pediatric cancer patients, today announced that it intends to offer its common shares in an underwritten public offering. In
addition, Fennec intends to grant the underwriters a 30-day option to purchase up to an additional 15% of its common shares offered
in the public offering.
Cantor Fitzgerald & Co. is acting as
the sole book-running manager for the proposed offering. Wedbush PacGrow is
acting as the co-manager.
The common shares are being offered by
the Company pursuant to a registration statement previously filed with and declared effective by the Securities and Exchange Commission
(the "SEC"). The offering will be made only by means of a prospectus. A preliminary prospectus supplement and an accompanying
prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov.
Copies of the preliminary prospectus supplement and the accompanying prospectus, when filed with the SEC, may also be obtained
from Cantor Fitzgerald & Co., 499 Park Avenue, 6th Floor, New York, NY 10022, Attn: Capital Markets Department,
or by email at prospectus@cantor.com.
This press release shall not constitute
an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities, in any
state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction. The securities will not be offered or sold, directly or indirectly, in Canada
or to any resident of Canada.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty
pharmaceutical company focused on the development of PEDMARK for the prevention of platinum-induced ototoxicity in
pediatric patients. Further, PEDMARK has received Orphan Drug Designation in the U.S. for this potential use. The FDA has
accepted for filing the Company's New Drug Application (NDA) for PEDMARK and has granted Priority Review. Fennec has
a license agreement with Oregon Health and Science University (OHSU) for exclusive worldwide license rights to intellectual
property directed to sodium thiosulfate and its use for chemoprotection, including the prevention of ototoxicity induced by platinum
chemotherapy, in humans.
Forward Looking Statements
Except for historical information described
in this press release, all other statements are forward-looking. These forward-looking statements include, among other things,
statements regarding the Company's expectations on the timing, size and completion of the offering. Forward-looking statements
are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary,
including such risks as unforeseen global instability, including political instability, or instability from an outbreak of pandemic
or contagious disease, such as the novel coronavirus (COVID-19), or surrounding the duration and severity of an outbreak, that
regulatory and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt
of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered
by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available
market for the Company's product will not be as large as expected, the Company's product will not be able to penetrate
one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may
not meet its future capital requirements, and other risks detailed from time to time in the Company's filings with the Securities
and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2019. Fennec Pharmaceuticals
Inc. disclaims any obligation to update these forward-looking statements except as required by law.
For further information, please contact:
Chief Executive Officer
Fennec Pharmaceuticals Inc.